We have located links that may give you full text access.
Tapentadol (Nucynta)--a new analgesic.
Medical Letter on Drugs and Therapeutics 2009 August 11
The FDA has approved tapentadol hydrochloride (Nucynta--Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients >18 years old. It has been classified as a Schedule II controlled substance. Tapentadol (Nucynta) is a centrally acting oral analgesic with opioid and adrenergic activity. In studies published to date, it was as effective as oxycodone or morphine with a lower incidence of gastrointestinal adverse effects, but until more data become available, older analgesics are preferred.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app